OncoGenex: Safety Monitoring Board Recommends Continuation Of Borealis-2 Trial

(RTTNews) - OncoGenex Pharmaceuticals, Inc. (OGXI) announced the independent Data Safety Monitoring Board has recommended that the Phase 2 Borealis-2 trial continue as planned after completing the pre-specified futility analysis. Borealis-2 is evaluating apatorsen in combination with docetaxel treatment in patients with metastatic bladder cancer.

The company said investigators have concluded in the bladder cancer trials conducted to date that 600mg apatorsen administered intravenously and all apatorsen doses administered intravesically have been well tolerated.